NewAmsterdam Pharma Co. NV (NAMS)
27.32
+0.46
(+1.73%)
USD |
NASDAQ |
Aug 25, 16:00
27.34
+0.02
(+0.09%)
After-Hours: 19:59
NewAmsterdam Pharma EPS Diluted (Quarterly) : -0.5199 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5199 |
| March 31, 2026 | -0.398 |
| December 31, 2025 | -0.6549 |
| September 30, 2025 | -0.6051 |
| June 30, 2025 | -0.1465 |
| March 31, 2025 | -0.3404 |
| December 31, 2024 | -0.95 |
| September 30, 2024 | -0.1757 |
| June 30, 2024 | -0.4118 |
| Date | Value |
|---|---|
| March 31, 2024 | -1.061 |
| September 30, 2022 | -0.2693 |
| June 30, 2022 | -0.0661 |
| March 31, 2022 | 0.078 |
| December 31, 2021 | 0.0524 |
| September 30, 2021 | 0.0975 |
| June 30, 2021 | -0.0732 |
| March 31, 2021 | 0.1588 |
| December 31, 2020 | 0.0023 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ProQR Therapeutics NV | -0.0923 |
| Pharming Group NV | 0.02 |
| argenx SE | -- |
| Arcutis Biotherapeutics, Inc. | 0.1104 |
| Damora Therapeutics, Inc. | -0.5099 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -64.14M |
| Revenue (Quarterly) | 3.701M |
| Total Expenses (Quarterly) | 67.84M |
| Enterprise Value | 2.524B |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | -1.73K% |
| Earnings Yield | -7.97% |
| Normalized Earnings Yield | -7.148 |